MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$358,473,000
(-224.82%↓ Y/Y)
Unrealized gain (loss) on
securities
$1,119,000
(746.82%↑ Y/Y)
Foreign currency
translation gain (loss)
$47,000
(120.80%↑ Y/Y)
Interest income, net
$33,704,000
(-17.67%↓ Y/Y)
Realized gain on
investments, net
$55,000
(-50.89%↓ Y/Y)
Net loss
-$359,639,000
(-227.05%↓ Y/Y)
Total other income,
net
$33,703,000
(-17.71%↓ Y/Y)
Amortization of financing
costs
$56,000
(-40.43%↓ Y/Y)
Loss from operations
-$393,342,000
(-160.63%↓ Y/Y)
Total operating
expenses
$393,342,000
(160.63%↑ Y/Y)
Research and development
$344,955,000
(239.38%↑ Y/Y)
General and
administrative
$48,387,000
(-1.81%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)
viking_9_15_logo-svg
Viking Therapeutics, Inc. (VKTX)